Flunisolide

Flunisolide
Clinical data
Trade names	Aerobid, Nasalide, Nasarel, others
Other names	6α-Fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione acetone cyclic 16,17-acetal
AHFS/Drugs.com	Monograph
MedlinePlus	a681048
Routes of; administration	Inhaled
ATC code	R01AD04 (WHO) R03BA03 (WHO);
Pharmacokinetic data
Protein binding	40% after inhalation
Elimination half-life	1.8 hours
Identifiers
	IUPAC name (1S,2S,4R,8S,9S,11S,12S,13R,19S)-19-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one;
CAS Number	3385-03-3 ;
PubChem CID	82153;
IUPHAR/BPS	7076;
DrugBank	DB00180 ;
ChemSpider	74144 ;
UNII	78M02AA8KF;
KEGG	D00324 ;
ChEBI	CHEBI:5106 ;
ChEMBL	ChEMBL1512 ;
CompTox Dashboard (EPA)	DTXSID1045534 ;
ECHA InfoCard	100.020.177
Chemical and physical data
Formula	C24H31FO6
Molar mass	434.504 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C\1\C=C/[C@]2(/C(=C/1)[C@@H](F)C[C@H]3[C@H]4[C@](C[C@H](O)[C@H]23)([C@@]5(OC(O[C@@H]5C4)(C)C)C(=O)CO)C)C;
	InChI InChI=1S/C24H31FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h5-7,13-14,16-17,19-20,26,28H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,20+,22-,23-,24+/m0/s1 ; Key:XSFJVAJPIHIPKU-XWCQMRHXSA-N ;
	(what is this?) (verify)

Flunisolide (marketed as AeroBid among others) is a corticosteroid often prescribed as a treatment for allergic rhinitis.^[1] Intranasal corticosteroids are the most effective medication for controlling symptoms.^[2]

Flunisolide's principal mechanism of action is to activate glucocorticoid receptors, indicating an anti-inflammatory action. The effects of topical corticosteroids are not immediate and must be used for at least a few days for noticeable relief. As-needed use is less effective than regular recommended use.^[2] Flunisolide should not be used for nasal infections. It should not be continued if symptoms are not relieved after regular use for over two to three weeks.^[3]

Patented in 1958 and approved for medical use in 1978,^[4] it is on the World Health Organization's List of Essential Medicines.^[5]

^ "Flunisolide". DrugBank.
^ ^a ^b Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA, et al. (August 2008). "The diagnosis and management of rhinitis: an updated practice parameter". The Journal of Allergy and Clinical Immunology. 122 (2 Suppl): S1-84. doi:10.1016/j.jaci.2008.06.003. PMID 18662584.
^ "Flunisolide Nasal Solution". DailyMed. U.S. National Library of Medicine.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 486. ISBN 9783527607495.
^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

[1] "Flunisolide". DrugBank.

[auto-2] Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA, et al. (August 2008). "The diagnosis and management of rhinitis: an updated practice parameter". The Journal of Allergy and Clinical Immunology. 122 (2 Suppl): S1-84. doi:10.1016/j.jaci.2008.06.003. PMID 18662584.

[nih.gov-3] "Flunisolide Nasal Solution". DailyMed. U.S. National Library of Medicine.

[Fis2006-4] Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 486. ISBN 9783527607495.

[WHO22nd-5] World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

[1]

[2]

[3]

[4]

[5]